Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laserscope KTP

This article was originally published in The Gray Sheet

Executive Summary

Laser system for treatment of benign prostatic hyperplasia (BPH) gains FDA market go-ahead, announced May 10. Commercial shipments are anticipated to begin later this year. Three-year follow-up data showing effectiveness comparable to TURP (trans-urethral resection of the prostate) will be presented at the American Urological Association meeting in Anaheim June 2-7
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT014869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel